Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 9OTHER 8NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Paclitaxel 8Doxorubicin 7Cisplatin 7Radiotherapy 4Filgrastim 4Chemotherapy, Adjuvant 3Tamoxifen 2Radiotherapy, Intensity-Modulated 2Observation 2Medroxyprogesterone 2Letrozole 2Ifosfamide 2Gene Expression Profiling 2Carboplatin 2Amifostine 2ridaforolimus 1perifosine 1lenvatinib 1irofulven 1abemaciclib 1X-Rays 1Trabectedin 1Therapeutics 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy, Adjuvant 1Polymerase Chain Reaction 1Phantoms, Imaging 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Endometrial Neoplasms × lenvatinib × Clear all
NCT03005015 2016-12-29

Lenvatinib in Second Line Endometrial Carcinoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡